The post OpenAI Finds AI Reasoning Models Cant Hide Their Thinking – A Win for Safety appeared on BitcoinEthereumNews.com. Caroline Bishop Mar 05, 2026 18:34The post OpenAI Finds AI Reasoning Models Cant Hide Their Thinking – A Win for Safety appeared on BitcoinEthereumNews.com. Caroline Bishop Mar 05, 2026 18:34

OpenAI Finds AI Reasoning Models Cant Hide Their Thinking – A Win for Safety

For feedback or concerns regarding this content, please contact us at [email protected]


Caroline Bishop
Mar 05, 2026 18:34

OpenAI’s new CoT-Control benchmark reveals frontier AI models struggle to obscure their reasoning chains, reinforcing monitoring as a viable safety layer.

OpenAI’s latest research reveals that frontier reasoning models—including GPT-5.2 Thinking—can’t reliably hide or manipulate their internal thought processes, even when explicitly instructed to do so. The finding, published March 5, 2026, suggests that chain-of-thought monitoring remains a viable safety mechanism as AI systems grow more autonomous.

The research team tested 13 reasoning models using CoT-Control, a new open-source evaluation suite comprising over 13,000 tasks. Models were given simple instructions about their reasoning—avoid certain keywords, use only lowercase letters, append specific phrases to sentences. They failed spectacularly.

Controllability scores ranged from just 0.1% to 15.4% across all frontier models tested. Even more telling: models often recognized mid-reasoning that they were violating instructions and still couldn’t course-correct. One example showed GPT-5.2 Thinking using the forbidden word “XOR” four additional times while actively panicking about having already used it.

Why This Matters for AI Development

As AI agents handle increasingly complex autonomous tasks, the ability to monitor their reasoning becomes critical. If models could deliberately obscure their thought processes when they know they’re being watched, safety evaluations would become unreliable. The research shows this isn’t currently possible.

“Low CoT controllability is a feature, not a bug,” the OpenAI team stated. The limitation makes chain-of-thought monitoring more trustworthy as a safeguard against misaligned behavior.

The data revealed some counterintuitive patterns. While larger models showed marginally better controllability, this advantage evaporated under two conditions: when models were given more time to think, and when they underwent additional reinforcement learning training. The OLMo-3-7B-RL-Zero-Math model saw its controllability score drop by more than tenfold during RL training.

Testing Under Adversarial Conditions

The researchers simulated realistic scenarios by explicitly telling models they were being monitored or evaluated. This slightly increased controllability—models tried harder—but gains remained modest and transferred poorly to new instruction types.

Automated prompt optimization found ways to boost controllability on training sets, but these improvements didn’t generalize. A model that learned to follow one type of CoT instruction still failed at novel ones.

The Bigger Picture

This work builds on OpenAI’s December 2025 framework for evaluating CoT monitorability, which found that inspecting reasoning traces catches misbehavior far more effectively than monitoring outputs alone. The March 2025 discovery of cheating behavior in reasoning models had prompted recommendations to preserve CoT monitoring capabilities.

OpenAI plans to report CoT controllability alongside monitorability metrics in system cards for future frontier models, starting with GPT-5.4 Thinking. The company has also committed to avoiding optimization pressure directly on the reasoning chains of frontier models—a practice that research suggests could inadvertently teach models to hide their intentions.

The open question remains whether this limitation persists as capabilities advance. The team acknowledges they don’t fully understand why controllability is low, making continued evaluation essential. For now, the inability of AI systems to game their own oversight represents an unexpected safety dividend.

Image source: Shutterstock

Source: https://blockchain.news/news/openai-cot-control-reasoning-models-safety-march-2026

Market Opportunity
Cosplay Token Logo
Cosplay Token Price(COT)
$0.00092
$0.00092$0.00092
0.00%
USD
Cosplay Token (COT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09